Open AccessGene therapy for bypass graft failure and restenosis
Author(s) -
Andrew H. Baker
Publication year - 2002
Publication title -
pathophysiology of haemostasis and thrombosis
Language(s) - English
Resource type - Journals
eISSN - 1424-8840
pISSN - 1424-8832
DOI - 10.1159/000073606
Subject(s) - genetic enhancement , restenosis , transgene , gene delivery , medicine , gene transfer , gene , viral vector , disease , intensive care medicine , bioinformatics , surgery , biology , recombinant dna , genetics , stent
Recently, it has become clear that the concept of gene therapy has changed. Whilst it was once thought that gene therapy merely required insertion of a transgene into a gene transfer vector with subsequent delivery to the target tissue to provide a therapeutic effect, this is now entirely too simplistic. Rather, there are many critical steps in the design and implementation of gene medicines and each step requires exhaustive testing and optimisation for a given target disease to increase efficiency and safety. Within cardiovascular diseases there are many potential target pathologies for gene-based interventions. Bypass graft failure and restenosis are two such examples.